Shukra Pharmaceuticals Ltd

SHUKRAPHAR

Watchlist

AI Mode

‌

Market Cap

₹ 2,352 Cr

P/E

198.93

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

MARKET LEADER

Valuation

OVERVALUED

Growth

EXCEPTIONAL

Profitability

HIGH MARGIN

Technicals

Bullish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Shukra Pharmaceuticals Limited, founded in 1993, specializes in manufacturing and trading pharmaceutical formulations and conducting laboratory testing. Their offerings include a wide range of antibiotics, antifungal, antiviral, sedatives, and more.

The company operates four key manufacturing divisions: tablets, capsules, liquid, and small volume parental, situated in Gujarat.

It collaborates with major pharmaceutical manufacturers like Cadila Healthcare, Intas Pharmaceuticals, and others, aiding in the development of diverse drugs and formulations.

In 2013-14, Shukra Pharmaceuticals underwent a significant restructuring, including the amalgamation of Proper Dealcomm Private Limited and re-organization through a high court-approved scheme.

The company provides a broad spectrum of dosage forms to prestigious pharmaceutical companies worldwide, enhancing its market presence and industry reputation.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Formulations

Market Cap

2,352 Cr

Volatility

Low Risk

P/E Ratio

198.9

Industry P/E

43.8

PEG Ratio

1.5

P/B Ratio

35.7

52W High

56.39

52W Low

8.00

Sales CAGR

-56.30%

16.73%

18.86%

10Y

23.57%

Profit CAGR

-48.33%

133.65%

206.15%

10Y

62.81%

ROE

TTM

18.17%

22.31%

18.83%

10Y

13.92%

ROCE

TTM

20.39%

23.44%

18.56%

10Y

13.48%

Technicals

Oscillators

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
SHUKRAPHAR	53.71	2,352 Cr	198.93	35.74	0.02	18.17	20.39	13.71
AMRUTANJAN	671.80	1,942 Cr	34.26	5.68	0.68	16.57	22.53	13.11
WINDLAS	778.20	1,647 Cr	24.47	3.08	0.74	12.60	16.43	8.27
BLISSGVS	143.40	1,510 Cr	13.78	1.33	0.35	9.68	14.69	8.24
SYNCOMF	15.05	1,412 Cr	22.42	3.73	0.00	16.66	22.00	13.82
HESTERBIO	1586.00	1,355 Cr	30.90	4.01	0.44	12.98	9.93	6.60
LINCOLN	487.00	968 Cr	12.10	1.35	0.37	11.18	15.34	9.36

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	20	25	19	11	3.18	5.56	11	13	5.39	5.88
Expenses	20	20	9.35	6.45	2.37	4.89	6.64	5.95	4.07	6.30
Operating Profit	0.34	5.09	9.54	4.43	0.81	0.67	3.94	7.32	1.32	-0.42
OPM %	1.69	20.66	50.50	40.72	25.47	12.05	37.24	55.16	24.49	-7.14
Other Income	0.63	0.24	0.56	1.38	0.72	1.02	1.01	1.47	1.11	1.71
Interest	0.08	0.06	0.07	0.07	0.06	0.11	0.15	0.27	0.27	0.29
Depreciation	0.46	0.56	0.51	0.52	0.67	0.70	0.70	0.94	0.79	0.81
Profit Before Tax	0.43	4.70	9.53	5.22	0.80	0.87	4.09	7.57	1.37	0.20
Tax %	2.33	-0.21	1.15	23.75	38.75	39.08	22.74	28.80	24.82	-1,090.00
Net Profit	0.42	4.71	9.42	3.99	0.49	0.54	3.16	5.39	1.03	2.38
EPS in Rs	0.01	0.04	0.22	0.09	0.01	0.01	0.07	0.12	0.02	0.05

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	5.15	5.75	6.61	14	11	20	59	75	33	35
Expenses	3.67	3.73	4.01	10	9.75	18	53	55	20	22
Operating Profit	1.47	2.02	2.60	3.43	1.44	2.89	5.36	19	13	13
OPM %	28.65	35.13	39.33	24.96	12.90	14.09	9.12	26.02	39.06	38.07
Other Income	0.07	0.11	0.04	0.01	0.16	0.08	1.20	2.82	4.21	4.61
Interest	0.01	0.04	0.00	0.00	0.03	0.29	0.28	0.29	0.59	0.80
Depreciation	0.47	0.74	0.96	1.48	1.47	1.66	1.84	2.05	3.00	3.13
Profit Before Tax	1.06	0.95	0.72	0.17	0.10	1.02	4.44	20	13	14
Tax %	52.49	44.44	36.22	79.16	-92.33	26.26	0.79	6.77	28.20	27.19
Net Profit	0.50	0.53	0.46	0.04	0.19	0.75	4.41	19	9.58	10
EPS in Rs	0.00	0.02	0.01	0.00	0.00	0.02	0.26	0.36	0.22	0.26
Dividend Payout %	15.58	14.88	16.95	0.00	0.00	10.44	1.91	5.91	4.55	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	1.57	1.57	1.57	1.57	1.57	1.57	1.57	3.91	11	44
Reserves	13	13	13	14	14	14	15	21	47	19
Borrowings	0.04	0.04	3.58	6.06	8.05	9.77	3.38	5.08	3.15	4.18
Other Liabilities	3.17	4.33	5.51	6.96	10	10	15	45	17	20
Total Liabilities	17	19	24	28	34	36	35	75	78	87
Fixed Assets	9.67	10	14	16	17	18	18	20	20	19
CWIP	1.68	1.64	1.66	1.66	1.66	1.66	1.66	1.66	1.66	1.95
Investments	0.04	0.04	0.05	0.05	0.05	0.19	0.00	0.00	0.00	0.00
Other Assets	5.88	7.08	8.27	11	14	16	16	53	56	65
Total Assets	17	19	24	28	34	36	35	75	78	87

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	2.72	-0.29	0.84	0.26	1.24	0.54	7.99	3.17	-5.20	7.92
Cash from Investing Activity	-0.41	-0.93	-4.75	-2.45	-3.36	-1.89	-1.53	-4.43	-1.20	-1.26
Cash from Financing Activity	-1.16	0.00	3.45	2.38	1.99	1.74	-6.68	4.94	12	-4.52
Net Cash Flow	1.15	-1.22	-0.46	0.18	-0.12	0.38	-0.21	3.68	6.01	2.14

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Aug 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	50.90%	50.90%	50.90%	50.90%	50.96%	50.96%	50.96%	50.96%	50.96%	50.96%	50.96%	50.96%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%
Public	48.99%	48.99%	48.99%	48.99%	48.93%	48.93%	48.93%	48.93%	48.93%	48.93%	48.93%	48.93%
Total Shareholders	9,531	9,582	9,600	9,747	10,963	12,974	14,989	16,321	17,844	18,231	20,337	21,441

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Overview

Detailed Summary

The company operates four key manufacturing divisions: tablets, capsules, liquid, and small volume parental, situated in Gujarat.

It collaborates with major pharmaceutical manufacturers like Cadila Healthcare, Intas Pharmaceuticals, and others, aiding in the development of diverse drugs and formulations.

In 2013-14, Shukra Pharmaceuticals underwent a significant restructuring, including the amalgamation of Proper Dealcomm Private Limited and re-organization through a high court-approved scheme.

The company provides a broad spectrum of dosage forms to prestigious pharmaceutical companies worldwide, enhancing its market presence and industry reputation.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Formulations

Market Cap

2,352 Cr

Volatility

Low Risk

P/E Ratio

198.9

Industry P/E

43.8

PEG Ratio

1.5

P/B Ratio

35.7

52W High

56.39

52W Low

8.00

Sales CAGR

-56.30%

16.73%

18.86%

10Y

23.57%

Profit CAGR

-48.33%

133.65%

206.15%

10Y

62.81%

ROE

TTM

18.17%

22.31%

18.83%

10Y

13.92%

ROCE

TTM

20.39%

23.44%

18.56%

10Y

13.48%

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
SHUKRAPHAR	53.71	2,352 Cr	198.93	35.74	0.02	18.17	20.39	13.71
AMRUTANJAN	671.80	1,942 Cr	34.26	5.68	0.68	16.57	22.53	13.11
WINDLAS	778.20	1,647 Cr	24.47	3.08	0.74	12.60	16.43	8.27
BLISSGVS	143.40	1,510 Cr	13.78	1.33	0.35	9.68	14.69	8.24
SYNCOMF	15.05	1,412 Cr	22.42	3.73	0.00	16.66	22.00	13.82
HESTERBIO	1586.00	1,355 Cr	30.90	4.01	0.44	12.98	9.93	6.60
LINCOLN	487.00	968 Cr	12.10	1.35	0.37	11.18	15.34	9.36